To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News | Article | Europe | European ＆ international partnerships | Chemistry
In April 2022, the SCBM (DMTS) was awarded funding from the Horizon Europe program for the ISOBIOTICS project, coordinated by Christophe Dugave. This project will enable the theoretical and practical training of 11 PhD students, including two at SCBM and one at SHFJ, on the development of innovative methods for the isotopic labeling of biological drugs such as peptides, proteins and oligonucleotides.
Developing a drug is a lengthy, regulated process which generally includes a drug discovery phase, during which molecules of interest are identified, followed by a preclinical research phase, during which drug candidates undergo proof-of-concept validation. This step, which requires the isotopic labeling of the numerous candidate molecules (with deuterium (2H), tritium (3H), carbon-11, carbon-14 or fluorine-18) in order to trace their pathway through the body, is very often a limiting stage in the process. The development of new methods for the simple, rapid and specific introduction of these isotopes into drug candidates is absolutely crucial. It is in this context that ISOTOPICS was launched in 2016, and ISOBIOTICS in 2023.
ISOBIOTICS (Isotopic Labeling of Biotherapeutics) is a european cross-sectoral Doctoral Network (DN, ex-ITN) that began in February 2023 and aims to provide immediate solutions to the most pressing problems concerning isotope labeling for the development of new bio-drugs. Biomolecules account for 55% of new drugs launched on the market in 2022, and almost 2/3 of pharmaceutical industry revenues. However, their isotopic labeling is tricky because of their large size, complexity and fragility. The challenge for ISOBIOTICS is therefore to design non-invasive methods for specific radiolabeling adapted to these particular molecules. Such radiolabeling strategies will i) advance the research and development of biotherapies that are more effective in terms of targeting and less immunogenic, and ii) train a new generation of radiochemists with a dual academic and industrial culture who will implement these methods to meet the needs of european industry. See also the ISOBIOTICS summary in our Europe web pages. Contact and coordination : Christophe Dugave email@example.com Phone : 33 1 69 08 99 38 - ISOBIOTICS website : https://www.isobiotics-project.org/ ISOBIOTICS official video - ISOBIOTICS Newsletter n°1 (summer 2023)
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.